|Mr. Olivier Brandicourt M.D.||Chief Exec. Officer and Director||5.77M||N/A||61|
|Mr. Jérôme Contamine||Chief Financial Officer and Exec. VP||N/A||N/A||60|
|Mr. Laurent Gilhodes||Principal Accounting Officer and VP of Corp. Accounting||N/A||N/A||N/A|
|Mr. Bruno Ménard||Chief Information officer||N/A||N/A||N/A|
|Mr. Sébastien Martel||VP of Investor Relations||N/A||N/A||N/A|
Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, a immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Lantus, Apidra, and Insuman human insulins; Toujeo, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; and Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug to treat cardiovascular diseases. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Sanofi’s ISS Governance QualityScore as of June 2, 2017 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 5; Compensation: 1.